Trial reportScientific reports2026
Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the efficacy of triplet chemotherapy (gemcitabine, cisplatin, and nab-paclitaxel) to the standard of care in locally advanced or metastatic gall bladder cancer. A total of 60 patients with locally advanced (unresectable) and metastatic gall bladder cancer were randomized to either of the 2 arms. Arm A received two drugs gemcitabine and cisplatin and arm B received three drugs gemcitabine, cisplatin and nab-paclitaxel. The evaluation was done post 3 and 6 cycles of chemotherapy. Patients were then followed up every 6 months for 2 years to assess response rates (RR), progression-free survival (PFS), and overall survival (OS). The combination of gemcitabine and cisplatin (arm A) had an overall response rate of 13.3% whereas it was 61.9% in patients who received gemcitabine, cisplatin, and nab-paclitaxel (0.004). The median progression-free survival for patients who received gemcitabine and cisplatin was 4.5 months (95% CI, 4.0-4.9) compared to 7.6 months (95% CI, 3.9-11.2) for patients treated with gemcitabine, cisplatin, and nab-paclitaxel (p ≤ 0.05). There was no increase in grade 3 adverse events with the addition of nab-paclitaxel. This study showed promising results, with triplet chemotherapy having a significantly better overall response rate and median progression-free survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.